

Award Number: W81XWH-06-1-0725

TITLE: Role of the Tyrosine Phosphatase SHP-1 and Regulatory T Cells in Breast Cancer

PRINCIPAL INVESTIGATOR: Ulrike Lorenz, Ph.D.

CONTRACTING ORGANIZATION: University of Virginia
Charlottesville, VA 22908

REPORT DATE: September 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01-09-2007		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 SEP 2006 - 31 AUG 2007	
4. TITLE AND SUBTITLE Role of the Tyrosine Phosphatase SHP-1 and Regulatory T Cells in Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0725	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Ulrike Lorenz, Ph.D. E-Mail: ulorenz@virginia.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Virginia Charlottesville, VA 22908				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Uncontrolled proliferation of tumor cells due to failure of immune-surveillance has been linked to cancer development. Regulatory T cells (Treg) play a critical role in immune tolerance by suppressing immune responses to the body's own antigens. The tyrosine phosphatase SHP-1 is a well-known negative regulator of T cell signaling that also affects the generation of Treg cells. Interestingly, mice with decreased levels of SHP-1 protein show a high occurrence of breast cancer. The objective of the studies proposed in the concept award is to test the hypothesis that the CD4+CD25+ regulatory T cell population plays a role in the increased incidence of breast tumors we have observed in me/+ mice. During the first year of the award, we have characterized transgenic mice expressing a dominant negative mutant of SHP-1 in the T cell lineage. Analyses of these mice have demonstrated a T cell autonomous effect of SHP-1 as assessed by TCR/CD3-mediated hyper-proliferation of the mice expressing the dominant negative mutant compared to non-expressers. Moreover in preliminary data, it was observed that expressers show an increase in CD4+CD25+ Treg cells compared to non-expressers making these transgenic mice a powerful model system to directly test the hypothesis that SHP-1 deficiency promotes the development/onset of breast cancer by increasing the number of regulatory T cells.					
15. SUBJECT TERMS Regulatory T Cells, Protein Tyrosine Phosphatase, Tumor Immunology					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	8	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusion.....	8
References.....	8
Appendices.....	8

Annual Report (Year 1) for Concept Award “Role of the Tyrosine Phosphatase SHP-1 and Regulatory T cells in Breast Cancer”


Introduction

The failure of immune-surveillance by the body allowing uncontrolled proliferation of tumor cells has been linked to cancer development. Regulatory T cells (T_{reg}) play a critical role in immune tolerance to self by suppressing immune responses to autoantigens. For a variety of cancers, including breast cancer, increased T_{reg} cell numbers have been reported. The tyrosine phosphatase SHP-1 is a well-recognized negative regulator of T cell signaling that also affects the generation of T_{reg} cells (1). Interestingly, mice heterozygous for the *motheaten* (*me*) allele, which express decreased SHP-1 protein levels, show a high occurrence of breast cancer. The objective of the studies proposed in the concept award is to test the hypothesis that the CD4+CD25+ regulatory T cell population plays a role in the increased incidence of breast tumors we have observed in *me/+* mice.

Body

As we had briefly outlined in our request for a no-cost extension of this award, over the last year, we encountered a number of unexpected difficulties in animal husbandry due to problems in the animal facility, which were beyond our control. These circumstances prevented us from analyzing *me/+* and *+/+* older mice as proposed in aim 1 of our original objectives, but instead we focused our studies on characterizing the newly generated transgenic mice that are the basis of aim 2.

The original hypothesis of aim 2 was to test whether the increased incidence of breast cancer in *me/+* mice is specifically due to impaired SHP-1 function in the T cell lineage. In order to address this question, we have generated mice that carry dominant negative mutants of SHP-1 (C453S and D419A) using the Cre/loxP system sites (2, 3). that allows tissue-specific expression upon crossing into Cre-expressing mouse strains (Fig. 1). We have obtained 2 (C453S) and 4 (D419A) independent transgenic lines that are currently further characterized.



Upon crossing with Lck-Cre mice, expression of the SHP-1 mutants is targeted to the T cell lineage. Analysis of the first generations of mice showed lineage-specific expression as assessed by western blotting (Fig. 2A) and flow cytometry (Fig. 2B-C).

To evaluate whether the putative dominant negative mutants for their effect on TCR-mediated signaling, we assessed TCR/CD3-driven proliferation in mice expressing dominant negative SHP-1 in the T cell lineage. In particular, TCR-induced proliferation of splenic T cells derived from SHP-1 D419A and *lck*-Cre double transgenic mice or the control mice single transgenic for either SHP-1 D419A or *lck*-Cre. As shown in Fig. 3, T cells derived from double transgenic 12-14-week old mice were hypersensitive to TCR stimulation. Interestingly, the 2-3 fold leftward shift observed in mice expressing the dominant negative SHP-1 mutant compared to controls is highly similar to the phenotype observed in SHP-1-deficient *me/me* T cells (4, 5). We are very encouraged by this finding, since it further validates that T cell-specific expression of the SHP-1 D419A mutant mimicks the *me/me* T cell phenotype. Moreover, since only the T cell lineage was affected by the loss of SHP-1 in these





Figure 3: T cells from transgenic mice expressing dominant negative mutant of SHP-1 are hyper-sensitive to TCR/CD3 stimulation. Proliferative response of T cells derived from single (SHP-1 D419A) or double (SHP-1 D419A : *lck-Cre*) transgenic mice in response to increasing amounts of anti-CD3 ϵ antibody (2c11). Splenocytes were enriched for T cells using negative selection via magnetic beads (Miltenyi). 5×10^4 T cells were stimulated with the indicated concentrations of plate-bound anti-CD3 ϵ . After 72 hrs., cells were pulsed with 1 μ Ci of [3 H] Thymidine for 18 hrs. [3 H] Thymidine incorporation was measured using a cell harvester. The data are presented as percentage of maximal incorporated counts at the highest concentration of anti-CD3 ϵ . In general maximal incorporation was ~200,000 cpm. The two graphs represent experiments using offspring (~3 month old) from two different founder mice (DA-1 and DA-2). Error bars represent the standard deviation of the mean.



experiments, rather than the entire hematopoietic system as in *me/me* mice, it suggests a T cell-autonomous effect of SHP-1.

We then assessed whether expression of the D419A mutant solely in the T cell lineage affects the number of CD4+CD25+ Treg cells in these transgenic mice. A preliminary analysis of spleen and lymph nodes of a limited number of mice showed a promising statistically significant increase in the number of CD4+CD25+ Treg cells in mice expressing the D419A mutant compared to non-expressers (Tab. 1). We realize that these are preliminary data; however, the observed increase in CD4+CD25+ Treg cells is again comparable to our previous data obtained from *me/me* mice (1). Thus this further supports the feasibility of the proposed studies to test the hypothesis that increased numbers of Treg cells contribute to the development of breast cancer. We are currently backcrossing the transgenic mice into the BALB/c strain, since breast cancer is more often detected in this genetic background compared to the C57/B6 background the mice are currently in. Backcrossing, Treg analyses and observation for the onset of breast cancer will be the focus of this research during the second year of the concept award.

genotype	N	CD4 T cells (%)	CD4+CD25+ (% within CD4+ population)	p value
Lymph node				
SHP-1 D419A- / Lck-Cre+	3 (4)	47.0±4.3 (44.9±5.6)	5.0±0.9 (5.7 ± 1.8)	0.0057 (0.1364)
SHP-1 D419A+ / Lck-Cre+	4	42.2±4.5	7.0 ±0.2	
Spleen				
SHP-1 D419A- / Lck-Cre+	3 (4)	19.3±0.5 (18.2±2.6)	6.9±1.3 (7.7 ±2.1)	0.0174 (0.0949)
SHP-1 D419A+ / Lck-Cre+	4	13.7 ±1.9	9.9±1.0	

Table 1: CD4+CD25+ Treg cell analyses of D419A expressing and non-expressing mice. N=number of mice analyzed in each group. Initially 4 mice were analyzed in each group. However upon further analysis, one outlier was identified in the SHP-1 D419A- / Lck-Cre+ group and based on the Grubb's test for outliers, this data point was omitted for the final analysis. Data including this outlier are provided in parentheses. p values were calculated for the changes in percentages of CD4+CD25+ Treg cells within the CD4 T cell population. Statistical analyses showed a statistically significant increase in the percentage of Treg cells both in the lymph nodes as well as in the spleen of mice expressing the SHP-1 D419A mutant compared to non-expressing mice.

Key Research Accomplishments

- Generation of transgenic mice expressing the SHP-1 D419A mutant specifically in the T cell lineage
- D419A expressers show T cell autonomous effect of SHP-1 as assessed by TCR/CD3-mediated hyper-proliferation
- D419A expressers show increased numbers of CD4+CD25+ Treg cells

Reportable Outcomes

Not yet

Conclusion

Based on the preliminary data obtained from the SHP-1 D419A/Lck-Cre mice, which demonstrate a T cell autonomous effect of SHP-1 as evidenced by effects on T cell proliferation and increased CD4+CD25+ Treg numbers, we conclude that the approach proposed in aim 2 (analysis of mice deficient in SHP-1 activity in the T cell lineage) of our original application is feasible and is in fact better suited than the alternative approach of the original aim 1 (analysis of mice deficient in SHP-1 activity in all SHP-1-expressing lineages) to directly address the hypothesis that SHP-1 deficiency promotes the development/onset of breast cancer by increasing the number of regulatory T cells. During the second year of this award, we will therefore focus our effort on this part of the original proposal.

References

1. Carter, J. D., G. Calabrese, M. Naganuma, and U. Lorenz. 2005. Deficiency of the Src homology region 2 domain-containing phosphatase 1 (SHP-1) causes enrichment of CD4+CD25+ regulatory T cells. *Journal of Immunology* 174:6627-6638.
2. Lakso, M., B. Sauer, B. Mosinger, Jr., E. J. Lee, R. W. Manning, S. H. Yu, K. L. Mulder, and H. Westphal. 1992. Targeted oncogene activation by site-specific recombination in transgenic mice. *Proc Natl Acad Sci U S A* 89:6232-6236.
3. Zhang, L., V. Camerini, T. P. Bender, and K. S. Ravichandran. 2002. A nonredundant role for the adapter protein Shc in thymic T cell development. *Nat Immunol* 3:749-755.
4. Lorenz, U., K. S. Ravichandran, S. J. Burakoff, and B. G. Neel. 1996. Lack of SHPTP1 results in src-family kinase hyperactivation and thymocyte hyperresponsiveness. *Proc Natl Acad Sci U S A* 93:9624-9629.
5. Carter, J. D., B. G. Neel, and U. Lorenz. 1999. The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. *Int Immunol* 11:1999-2014.

Appendices

Not applicable